查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096920

氣喘吸入器市場－2026-2032年全球市場預測

Asthma Inhalers Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，氣喘吸入器市場將成長至 190.7 億美元，複合年成長率為 10.98%。

主要市場統計數據
基準年 2025 92億美元
預計年份：2026年 101.9億美元
預測年份 2032 190.7億美元
複合年成長率 (%) 10.98%

氣喘吸入器執行摘要

氣喘吸入器在成人和兒童氣喘患者的長期管理、快速緩解症狀以及預防嚴重急性發作方面仍然發揮核心作用。此類吸入器包括壓力定量吸入器、乾粉吸入器、緩霧吸入器、呼吸道吸入器以及用於安寧療護和維持治療的連接式吸入器平台。氣喘診斷率的上升、都市區空氣污染、過敏原暴露、菸草煙霧、職業刺激物、呼吸道感染疾病以及臨床上日益重視藥物依從性、吸入技巧掌握和個體化疾病管理等因素，都推動了吸入器需求的成長。

氣喘吸入器市場發生變革性變化

隨著醫療保健系統從氣喘發作時的緊急治療轉向基於指南的呼吸系統疾病預防管理，氣喘吸入器的市場格局正在發生顯著變化。其中最顯著的變化之一是，人們越來越傾向於使用包含吸入性皮質類固醇的治療方案來減少氣喘急性發作，尤其是在臨床方案推薦使用抗發炎急救藥物或採用維持治療和急救治療相結合的方案時。這一趨勢正在改變臨床醫生評估吸入療法的方式，他們更加重視疾病的嚴重程度、既往急性發作史、用藥依從性以及患者正確使用特定裝置的能力。

人工智慧對氣喘吸入器的累積影響

人工智慧 (AI) 透過改善診斷支援、個人化治療、藥物依從性監測和急性發作風險預測，對氣喘吸入器產生了日益顯著的影響。 AI 驅動的智慧吸入器系統可以分析給藥時間、漏服維持藥物、過度使用緩解藥物、吸入流速、與位置資訊相關的症狀誘因以及環境暴露數據等模式。這些資訊有助於臨床醫師及早發現控制不佳的氣喘，並及時調整治療方案。

氣喘吸入器的關鍵區域見解

亞太地區呼吸系統疾病負擔沉重，都市化迅速，空氣品質面臨挑戰，且氣喘診斷治療的覆蓋範圍不斷擴大。中國和印度由於患者人數眾多、污染嚴重以及醫療基礎設施不斷完善，在區域需求趨勢中扮演核心角色。同時，日本、韓國和澳洲在基於指南的管理、醫療設備品質標準以及數位醫療的應用方面更為先進。該地區的優先事項包括治療費用的可負擔性、維持治療藥物的可及性以及吸入技術的教育。

氣喘吸入器的關鍵團體見解

北約成員國的呼吸系統護理體系與北美和高所得歐洲國家的呼吸系統護理體係有顯著重疊，這些國家的供應鏈韌性、藥品供應穩定性、品質標準以及醫療保健系統的發展都會影響吸入器的採購和取得策略。七國集團（G7）國家通常在呼吸系統疾病指南的執行方面更為完善，監管體系更為先進，維持治療藥物的可及性更高，並且數位化監測和永續性的整合程度也更高。這些國家在評估低碳吸入器取得途徑的同時，也更積極確保吸入器能夠滿足患者的特定臨床需求。

來自主要國家關於氣喘吸入器的見解

在中國，呼吸系統疾病的診療正透過診斷系統的擴展、醫院基礎設施的改善、國內生產能力的提升以及人們對空氣污染相關呼吸系統疾病認知的不斷提高而發展。在美國，一個高度發展的氣喘吸入器生態系統正在構建，其發展受到專科醫生和基層醫療醫生處方、保險覆蓋範圍趨勢、藥房干預以及數位化呼吸工具日益普及等因素的影響。日本面臨人口老化、對高品質醫療設備的期望以及系統性呼吸系統疾病管理等多重挑戰。印度的氣喘負擔沉重，儘管都市區的醫療保健服務正在不斷擴展，但費用問題、診斷不足、吸入器接受度和正確使用仍然是亟待解決的重大挑戰。

為行業領導者提供的實用建議

行業領導者應優先考慮以患者為中心的吸入器設計，以提高易用性、減少誤用，並幫助兒童、成人、老年人和吸氣流量受限的患者提高用藥依從性。產品策略應與目前的氣喘指南保持一致，尤其要重視抗發炎療法的推廣和減少對單純安寧療護的依賴。清晰的教育材料、設備演示課程和藥劑師培訓支援能夠顯著改善臨床療效。

調查方法

本執行摘要的調查方法是基於對檢驗的二手研究、臨床指南審查、監管分析、公共衛生證據以及呼吸系統護理趨勢的整合。資訊來源通常包括國家和國際氣喘管理指南、衛生部門出版刊物、同行評審的呼吸醫學文獻、來自權威公共衛生機構的流行病學證據、環境政策文件以及與吸入療法和醫療設備相關的監管指南。

結論

氣喘吸入器正從傳統的藥物輸送裝置發展成為用於精準呼吸護理的整合工具。在臨床實踐中，重點正轉向預防氣喘急性發作、提高維持治療的依從性以及加強與指南推薦的抗發炎治療策略的契合度。同時，智慧吸入器、人工智慧監測和數位化指導正在創造新的機遇，以便及早發現控制不佳的氣喘並支持個人化干預。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：氣喘吸入器市場：依產品類型分類

  • 乾粉吸入器
  • 定量噴霧吸入器
  • 緩霧吸入器

第8章：氣喘吸入器市場：依藥物類別分類

  • 抗膽鹼能藥物
    • 長效毒蕈鹼受體拮抗劑
    • 短效毒蕈鹼受體拮抗劑
  • 聯合治療
    • ICS/LABA
    • ICS/SABA
  • 吸入性皮質類固醇
  • 長效BETA-激動劑
  • 短效BETA-激動劑

第9章：氣喘吸入器市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第10章：氣喘吸入器市場：依劑型管道分類

  • 氣霧劑型
  • 粉末基
  • 液體懸浮劑配方
  • 燃氣驅動

第11章：氣喘吸入器市場：依通路分類

  • 醫院藥房
    • 急性護理
    • 專科診所藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第12章：氣喘吸入器市場：依處方類型分類

  • 根據處方箋
  • 非處方藥

第13章：氣喘吸入器市場：依最終用途分類

  • 居家照護
  • 臨床和醫院用途

第14章氣喘吸入器市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第15章：氣喘吸入器市場：依類別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第16章：氣喘吸入器市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AMIKO Digital Health
  • Armstrong Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • CHIESI Farmaceutici SpA
  • Cipla Limited
  • Cohero Health, Inc.
  • GlaxoSmithKline PLC
  • H&T Presspart
  • HELTMAN Medikal AS
  • Koninklijke Philips NV
  • Luckys Pharma
  • Merck & Co., Inc.
  • Microlife Corporation
  • Novartis AG
  • Nutra Respiro
  • Omron Corporation
  • OPKO Health, Inc.
  • PARI GmbH
  • Pulmatrix, Inc.
  • Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Ultratech India Ltd.
Product Code: MRR-AD517FAA7F57

The Asthma Inhalers Market is projected to grow by USD 19.07 billion at a CAGR of 10.98% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.20 billion
Estimated Year [2026] USD 10.19 billion
Forecast Year [2032] USD 19.07 billion
CAGR (%) 10.98%

Asthma Inhalers Executive Summary

Asthma inhalers remain central to long-term asthma control, rapid symptom relief, and prevention of severe exacerbations across adult and pediatric populations. The category includes pressurized metered-dose inhalers, dry powder inhalers, soft mist inhalers, breath-actuated inhalers, and connected inhaler platforms used with reliever and controller therapies. Demand is shaped by rising diagnosed asthma prevalence, urban air pollution, allergen exposure, tobacco smoke, occupational irritants, respiratory infections, and stronger clinical emphasis on adherence, inhaler technique, and personalized disease management.

Current clinical guidance increasingly discourages reliance on short-acting bronchodilator-only strategies for many patients and supports inhaled corticosteroid-containing approaches that reduce exacerbation risk. This is reshaping prescribing behavior, patient education, and device selection. At the same time, sustainability pressures are accelerating evaluation of lower-emission inhaler options, while digital health tools are improving monitoring, dose tracking, and real-world evidence generation. The asthma inhalers landscape is therefore evolving from a device-and-drug delivery segment into an integrated respiratory care ecosystem focused on outcomes, access, adherence, and environmental responsibility.

Transformative Shifts in the Asthma Inhalers Landscape

The asthma inhalers landscape is undergoing significant transformation as healthcare systems move from episodic rescue care toward proactive, guideline-aligned respiratory disease management. One of the most important shifts is the growing preference for inhaled corticosteroid-containing regimens to reduce exacerbations, particularly where clinical protocols support anti-inflammatory reliever or maintenance-and-reliever approaches. This trend is changing how clinicians evaluate inhaler therapy, placing greater importance on disease severity, exacerbation history, adherence patterns, and patient ability to use specific devices correctly.

Device innovation is another major force. Breath-actuated designs, dose counters, ergonomic improvements, spacer compatibility, and connected sensors are helping address persistent challenges such as poor inhaler technique and underuse of controller therapy. Environmental policy is also influencing procurement and prescribing, especially in regions scrutinizing hydrofluoroalkane propellants in pressurized metered-dose inhalers. As a result, dry powder inhalers and next-generation low-global-warming-potential propellant devices are receiving increased attention, provided clinical suitability and patient access are maintained.

Healthcare delivery models are also shifting. Pharmacist-led inhaler technique checks, remote monitoring, telehealth-supported asthma reviews, and school- or community-based asthma programs are becoming more important in reducing avoidable emergency visits. Collectively, these changes are pushing the industry toward inhalers that are clinically effective, easy to use, digitally enabled, environmentally conscious, and compatible with value-based care priorities.

Cumulative Impact of Artificial Intelligence on Asthma Inhalers

Artificial intelligence is increasingly influencing asthma inhalers by improving diagnosis support, treatment personalization, adherence monitoring, and exacerbation risk prediction. AI-enabled connected inhaler systems can analyze patterns such as dose timing, missed controller doses, reliever overuse, inhalation flow, location-linked symptom triggers, and environmental exposure data. These insights can help clinicians identify uncontrolled asthma earlier and support timely treatment adjustments.

In clinical workflows, AI can assist with stratifying patients by exacerbation risk, flagging excessive short-acting reliever use, and integrating spirometry, symptom scores, electronic health records, and patient-reported outcomes. For patients, AI-driven reminders, coaching tools, and mobile applications can reinforce proper inhaler technique and medication routines. In population health, aggregated and anonymized inhaler-use data can help healthcare organizations identify geographic clusters of poor control, seasonal trigger patterns, and gaps in access to preventive therapy.

The cumulative impact of AI will depend on data quality, interoperability, regulatory oversight, cybersecurity, and equitable access. Algorithms must be validated across age groups, ethnicities, disease severities, device types, and healthcare settings to avoid bias. When implemented responsibly, AI can move asthma inhalers beyond passive drug delivery toward intelligent respiratory care, enabling earlier intervention, improved adherence, and more efficient use of healthcare resources.

Key Regional Insights for Asthma Inhalers

Asia-Pacific is characterized by high respiratory disease burden, rapid urbanization, air quality challenges, and expanding access to diagnosed asthma care. China and India are central to regional demand dynamics due to large patient populations, pollution exposure, and growing healthcare infrastructure, while Japan, South Korea, and Australia show stronger integration of guideline-based management, device quality standards, and digital health adoption. Regional priorities include affordability, availability of controller therapy, and education on inhaler technique.

Europe is shaped by strong respiratory guidelines, sustainability policies, and structured primary care management, with healthcare systems increasingly balancing clinical appropriateness with lower-carbon inhaler choices. Countries across the region emphasize inhaled corticosteroid adherence, patient instruction, pharmacovigilance, and environmental assessment of inhaler propellants. North America has mature asthma management pathways, strong use of prescription inhaler therapies, and increasing adoption of connected respiratory monitoring. The United States and Canada emphasize guideline adherence, payer coverage, pharmacy-based education, and efforts to reduce emergency care linked to uncontrolled asthma. Environmental evaluation of inhaler propellants and patient access to preventive therapies are prominent policy and clinical themes.

Latin America demonstrates rising focus on improving diagnosis, expanding access to essential inhaled medicines, and addressing disparities between urban and rural care. Brazil and Mexico are important regional anchors, with public health systems and private care channels both influencing inhaler availability. Africa remains highly diverse, with key challenges including underdiagnosis, affordability, inconsistent access to controller inhalers, and limited specialist availability; however, stronger primary care programs and essential medicine initiatives are improving awareness and treatment pathways. The Middle East faces asthma burden associated with dust exposure, climate conditions, smoking, and urban development, while Gulf health systems are investing in specialty care and digital health infrastructure.

Key Group Insights for Asthma Inhalers

NATO countries overlap significantly with high-income respiratory care systems in North America and Europe, where supply chain resilience, medicine security, quality standards, and healthcare preparedness influence inhaler procurement and access strategies. G7 countries generally show stronger respiratory guideline implementation, advanced regulatory systems, broad availability of controller therapy, and higher integration of digital monitoring and sustainability priorities. These countries are also more active in evaluating lower-carbon inhaler pathways while maintaining patient-specific clinical suitability.

BRICS countries collectively represent a diverse asthma inhalers landscape shaped by large populations, air pollution exposure, expanding domestic healthcare capacity, and growing emphasis on affordable inhaled medicines. China, India, Brazil, Russia, and South Africa differ in reimbursement, access, and clinical infrastructure, but all share the need to improve early diagnosis, controller therapy adherence, and correct inhaler technique. The European Union is a key driver of sustainability-oriented inhaler policy, clinical standardization, pharmacovigilance, and access to evidence-based asthma care. EU healthcare systems are increasingly evaluating device carbon footprint alongside safety, efficacy, patient preference, and correct-use feasibility.

ASEAN markets reflect varied healthcare maturity, with urban centers showing increased asthma diagnosis, pharmacy access, and adoption of inhaled therapies, while rural areas continue to face barriers related to affordability, healthcare workforce capacity, and patient education. Air pollution, biomass smoke exposure, and climate-linked respiratory triggers support the need for stronger preventive asthma management and improved inhaler technique training across the region. The GCC is distinguished by high healthcare investment, expanding specialty respiratory services, and strong interest in digital health tools that support chronic disease management. Dust storms, extreme temperatures, indoor air quality issues, and smoking-related respiratory risk increase the importance of effective inhaler access and patient monitoring.

Key Country Insights for Asthma Inhalers

China is advancing respiratory care through expanded diagnosis, hospital infrastructure, domestic production capabilities, and rising awareness of pollution-related respiratory disease. The United States has a highly developed asthma inhalers ecosystem shaped by specialist and primary care prescribing, insurance coverage dynamics, pharmacy interventions, and growing use of digital respiratory tools. Japan combines aging-population needs, high device quality expectations, and structured respiratory management. India faces a substantial asthma burden, with affordability, underdiagnosis, inhaler acceptance, and correct technique remaining critical issues alongside growing urban healthcare access.

Germany demonstrates strong respiratory care infrastructure, structured reimbursement, and emphasis on device quality and patient instruction. The United Kingdom is prominent in sustainability-led inhaler policy, with clinical pathways increasingly considering low-carbon device choices where clinically appropriate. Australia has well-established asthma action plan practices and public health awareness, supported by attention to seasonal triggers, bushfire smoke, and preventive therapy. France continues to prioritize chronic disease management, pharmacy involvement, and appropriate use of controller therapy. South Korea shows strong digital health readiness, advanced clinical infrastructure, and growing focus on chronic respiratory disease monitoring and adherence support.

Italy and Spain maintain strong primary care and specialist respiratory networks supported by guideline-driven inhaler use and patient education initiatives. Canada emphasizes guideline-based asthma control, equitable access, and environmental considerations in inhaler selection. Russia faces regional variability in healthcare access and climatic respiratory triggers, making consistent availability and appropriate use of controller inhalers important. Brazil combines a large respiratory patient base with public and private healthcare channels, making affordability and consistent supply of inhaled corticosteroid therapies central priorities. Mexico is focused on improving access to diagnosis and controller medications while managing urban pollution and disparities across care settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize patient-centered inhaler design that improves usability, reduces technique errors, and supports adherence across children, adults, elderly patients, and individuals with limited inspiratory flow. Product strategies should align with current asthma guidelines, especially the shift toward anti-inflammatory treatment approaches and reduced dependence on reliever-only use. Clear education materials, device demonstration programs, and pharmacist-supported training can materially improve real-world outcomes.

Sustainability should be embedded into portfolio planning without compromising clinical appropriateness. Leaders should invest in lower-emission propellant innovation, dry powder inhaler optimization, recyclable components, responsible disposal programs, and transparent lifecycle evidence. Digital integration should focus on clinically useful features such as dose tracking, reliever overuse alerts, inhalation quality feedback, and interoperability with electronic health records.

Access strategies are equally important. Stakeholders should develop tiered pricing, essential medicine partnerships, local distribution strengthening, and public health collaborations in underserved markets. Regulatory and evidence-generation plans should include real-world adherence data, usability testing, environmental impact assessment, and validation across diverse populations. Organizations that combine efficacy, affordability, digital intelligence, sustainability, and patient education will be best positioned to support improved asthma control.

Research Methodology

The research methodology for this executive summary is based on verified secondary research, clinical guideline review, regulatory analysis, public health evidence, and synthesis of respiratory care trends. Sources typically include national and international asthma management guidelines, health authority publications, peer-reviewed respiratory medicine literature, epidemiological evidence from recognized public health institutions, environmental policy documentation, and regulatory guidance related to inhaled therapies and medical devices.

The analysis evaluates asthma inhalers across therapy role, device type, care setting, patient population, technology integration, sustainability considerations, and access dynamics. Regional, group, and country insights are developed by assessing healthcare infrastructure, disease burden indicators, reimbursement environments, clinical practice patterns, air quality and environmental risk factors, and policy priorities. Findings are cross-checked for consistency and limited to evidence-backed qualitative interpretation, avoiding unsupported claims, market sizing, market share, or forecasting.

Conclusion

Asthma inhalers are evolving from conventional drug delivery devices into integrated tools for precision respiratory care. Clinical practice is shifting toward exacerbation prevention, improved controller adherence, and better alignment with guideline-recommended anti-inflammatory treatment strategies. At the same time, connected inhalers, AI-enabled monitoring, and digital coaching are creating new opportunities to identify uncontrolled asthma earlier and support personalized intervention.

Regional differences remain substantial, with high-income markets focusing on sustainability, digital integration, and care optimization, while emerging markets prioritize affordability, diagnosis, and consistent access to essential inhaled medicines. The future direction of asthma inhalers will be shaped by the ability to balance clinical effectiveness, patient usability, environmental responsibility, and equitable access. Stakeholders that invest in evidence-based innovation, patient education, and resilient supply pathways can help reduce avoidable exacerbations and improve long-term asthma outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Asthma Inhalers Market, by Product Type

  • 7.1. Introduction
  • 7.2. Dry Powder Inhaler
  • 7.3. Metered Dose Inhaler
  • 7.4. Soft Mist Inhaler

8. Asthma Inhalers Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Anticholinergic
    • 8.2.1. Long Acting Muscarinic Antagonist
    • 8.2.2. Short Acting Muscarinic Antagonist
  • 8.3. Combination Therapy
    • 8.3.1. ICS/LABA
    • 8.3.2. ICS/SABA
  • 8.4. Inhaled Corticosteroid
  • 8.5. Long Acting Beta Agonist
  • 8.6. Short Acting Beta Agonist

9. Asthma Inhalers Market, by Age Group

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Asthma Inhalers Market, by Route of Drug Formulation

  • 10.1. Introduction
  • 10.2. Aerosol-based
  • 10.3. Powder-based
  • 10.4. Liquid Suspension Formulations
  • 10.5. Gas-propelled

11. Asthma Inhalers Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
    • 11.2.1. Acute Care
    • 11.2.2. Specialty Clinic Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy
    • 11.4.1. Chain Pharmacy
    • 11.4.2. Independent Pharmacy

12. Asthma Inhalers Market, by Prescription Type

  • 12.1. Introduction
  • 12.2. Prescription-based
  • 12.3. Over-the-Counter

13. Asthma Inhalers Market, by End-Use

  • 13.1. Introduction
  • 13.2. Homecare Use
  • 13.3. Clinical/Hospital Use

14. Asthma Inhalers Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. Europe
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Africa
  • 14.6. Middle East

15. Asthma Inhalers Market, by Group

  • 15.1. NATO
  • 15.2. G7
  • 15.3. BRICS
  • 15.4. European Union
  • 15.5. ASEAN
  • 15.6. GCC

16. Asthma Inhalers Market, by Country

  • 16.1. China
  • 16.2. United States
  • 16.3. Japan
  • 16.4. India
  • 16.5. Germany
  • 16.6. United Kingdom
  • 16.7. Australia
  • 16.8. France
  • 16.9. South Korea
  • 16.10. Italy
  • 16.11. Canada
  • 16.12. Russia
  • 16.13. Brazil
  • 16.14. Mexico
  • 16.15. Spain

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AMIKO Digital Health
  • 18.2. Armstrong Pharmaceuticals, Inc.
  • 18.3. AstraZeneca PLC
  • 18.4. Beximco Pharmaceuticals Ltd.
  • 18.5. Boehringer Ingelheim International GmbH
  • 18.6. Cadila Healthcare Ltd.
  • 18.7. CHIESI Farmaceutici S.p.A.
  • 18.8. Cipla Limited
  • 18.9. Cohero Health, Inc.
  • 18.10. GlaxoSmithKline PLC
  • 18.11. H&T Presspart
  • 18.12. HELTMAN Medikal A.S.
  • 18.13. Koninklijke Philips N.V.
  • 18.14. Luckys Pharma
  • 18.15. Merck & Co., Inc.
  • 18.16. Microlife Corporation
  • 18.17. Novartis AG
  • 18.18. Nutra Respiro
  • 18.19. Omron Corporation
  • 18.20. OPKO Health, Inc.
  • 18.21. PARI GmbH
  • 18.22. Pulmatrix, Inc.
  • 18.23. Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd.
  • 18.24. Teva Pharmaceutical Industries Ltd.
  • 18.25. Ultratech India Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA INHALERS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ASTHMA INHALERS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ASTHMA INHALERS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ASTHMA INHALERS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ASTHMA INHALERS MARKET SIZE, BY END-USE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ASTHMA INHALERS MARKET SIZE, BY END-USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ASTHMA INHALERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ASTHMA INHALERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ASTHMA INHALERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ASTHMA INHALERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ASTHMA INHALERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ASTHMA INHALERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ASTHMA INHALERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL ASTHMA INHALERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ASTHMA INHALERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRY POWDER INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRY POWDER INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRY POWDER INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL METERED DOSE INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL METERED DOSE INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METERED DOSE INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOFT MIST INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOFT MIST INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOFT MIST INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTICHOLINERGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTICHOLINERGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTICHOLINERGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LONG ACTING MUSCARINIC ANTAGONIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LONG ACTING MUSCARINIC ANTAGONIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG ACTING MUSCARINIC ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SHORT ACTING MUSCARINIC ANTAGONIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHORT ACTING MUSCARINIC ANTAGONIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SHORT ACTING MUSCARINIC ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ICS/LABA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ICS/LABA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ICS/LABA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ICS/SABA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ICS/SABA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ICS/SABA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INHALED CORTICOSTEROID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INHALED CORTICOSTEROID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INHALED CORTICOSTEROID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LONG ACTING BETA AGONIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LONG ACTING BETA AGONIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LONG ACTING BETA AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SHORT ACTING BETA AGONIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHORT ACTING BETA AGONIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SHORT ACTING BETA AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AEROSOL-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AEROSOL-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AEROSOL-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POWDER-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POWDER-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POWDER-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIQUID SUSPENSION FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIQUID SUSPENSION FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIQUID SUSPENSION FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GAS-PROPELLED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GAS-PROPELLED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GAS-PROPELLED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINIC PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CLINIC PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPECIALTY CLINIC PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHAIN PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHAIN PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHAIN PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRESCRIPTION-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PRESCRIPTION-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRESCRIPTION-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOMECARE USE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOMECARE USE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOMECARE USE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CLINICAL/HOSPITAL USE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CLINICAL/HOSPITAL USE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CLINICAL/HOSPITAL USE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ASTHMA INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ASTHMA INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ASTHMA INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ASTHMA INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ASTHMA INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ASTHMA INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ASTHMA INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ASTHMA INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ASTHMA INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 238. GCC ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 244. GCC ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. GCC ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL ASTHMA INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. JAPAN ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 280. JAPAN ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 281. JAPAN ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. JAPAN ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 283. INDIA ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. INDIA ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 287. INDIA ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. INDIA ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 325. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 326. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 328. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. AUSTRALIA ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. FRANCE ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. FRANCE ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 334. FRANCE ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 335. FRANCE ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 336. FRANCE ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 337. FRANCE ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 338. FRANCE ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 339. FRANCE ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 340. FRANCE ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 341. FRANCE ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. FRANCE ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 352. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 353. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. SOUTH KOREA ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 355. ITALY ASTHMA INHALERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 356. ITALY ASTHMA INHALERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. ITALY ASTHMA INHALERS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 358. ITALY ASTHMA INHALERS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2032 (USD MILLION)
  • TABLE 359. ITALY ASTHMA INHALERS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 360. ITALY ASTHMA INHALERS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 361. ITALY ASTHMA INHALERS MARKET SIZE, BY ROUTE OF DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 362. ITALY ASTHMA INHALERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 363. ITALY ASTHMA INHALERS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 364. ITALY ASTHMA INHALERS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 365. ITALY ASTHMA INHALERS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 366. ITALY ASTHMA INHALERS MARKET SIZE, BY END-USE, 2018-2032 (USD MILLION)
  • TABLE 367. CANADA ASTHMA INHALERS MARKET S